Published by maria gbaf
Posted on September 13, 2021
2 min readLast updated: February 11, 2026
Add as preferred source on Google
LONDON (Reuters) – Britain’s state-run National Health Service will on Monday begin the world’s biggest trial of Grail Inc’s flagship Galleri blood test that can be used to detect more than 50 types of cancer before symptoms appear.
The Galleri test looks at the DNA in a patient’s blood to determine if any come from cancer cells. Earlier diagnosis of cancers leads to dramatically increased survival rates.
The NHS said it wanted to recruit 140,000 volunteers in England to see how well the test worked as part of a randomised control trial. Half of the participants will have their blood sample screened with the Galleri test right away.
“We need to study the Galleri test carefully to find out whether it can significantly reduce the number of cancers diagnosed at a late stage,” said Peter Sasieni, professor of cancer prevention at King’s College London.
“The test could be a game changer for early cancer detection and we are excited to be leading this important research.”
Lung cancer is by far the most common cause of cancer death in the United Kingdom, accounting for around a fifth of all cancer deaths. Lung, bowel, prostate and breast cancers account for 45% of the United Kingdom’s cancer deaths, the NHS said.
U.S. life sciences company Illumina Inc said last month it had completed its $7.1 billion acquisition of Grail. Illumina said it will operate Grail separately from its existing business.
(Reporting by Guy Faulconbridge; Editing by Mike Harrison)
The Galleri test looks at the DNA in a patient's blood to determine if any come from cancer cells, enabling earlier diagnosis of cancers.
The NHS aims to recruit 140,000 volunteers in England to evaluate the effectiveness of the Galleri test.
Earlier diagnosis of cancers leads to dramatically increased survival rates, making early detection crucial.
Peter Sasieni, a professor of cancer prevention, emphasized the need to study the Galleri test carefully to assess its impact on late-stage cancer diagnoses.
U.S. life sciences company Illumina Inc completed its $7.1 billion acquisition of Grail, which will operate separately from Illumina's existing business.
Explore more articles in the Top Stories category
